Medicare Part D drugs starting with C
177 drugs start with C; 81 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Calquence in 2024: $1.7 billion, what plans and patients paid at the pharmacy before rebates.
Which drugs start with C?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Cabergoline | 100% | Tier 3 | $7 million |
| Cablivi (caplacizumab-yhdp) | 25.3% | Tier 5 | $25 million |
| Cabometyx (cabozantinib) | 100% | Tier 5 | $1.2 billion |
| Caffeine / ergotamine tartrate | 93.1% | Tier 3 | $3 million |
| Calcipotriene | 100% | Tier 3 | $24 million |
| Calcitriol | 100% | Tier 2 | $26 million |
| Calcium acetate | 34.7% | Tier 2 | no 2024 match |
| Calcium chloride / glucose / potassium chloride / sodium chloride / sodium lactate | 56% | Tier 4 | no 2024 match |
| Calcium chloride / magnesium chloride / potassium chloride / sodium acetate / sodium chloride | 68.8% | Tier 4 | no 2024 match |
| Calquence (acalabrutinib) | 100% | Tier 5 | $1.7 billion |
| Camila (norethindrone) | 95.8% | Tier 2 | $12 thousand |
| CamreseLo (ethinyl estradiol) | 68% | Tier 2 | no 2024 match |
| Camzyos (mavacamten) | 10.4% | Tier 5 | $291 million |
| Canasa (mesalamine) | under 0.1% | Tier 1 | $1 million |
| Candesartan cilexetil | 100% | Tier 1 | $40 million |
| Candesartan cilexetil / hydrochlorothiazide | 90.9% | Tier 1 | $14 million |
| Caplyta (lumateperone) | 100% | Tier 5 | $268 million |
| Caprelsa (vandetanib) | 100% | Tier 5 | $3 million |
| Captopril | 99% | Tier 1 | $5 million |
| Carafate (sucralfate) | 0.4% | Tier 1 | $1 million |
| Carbaglu (carglumic acid) | 0.2% | Tier 1 | $11 million |
| Carbamazepine | 100% | Tier 2 | $97 million |
| Carbatrol (carbamazepine) | 2.3% | Tier 2 | $3 million |
| Carbidopa | 84.4% | Tier 4 | $7 million |
| Carbidopa / entacapone / levodopa | 92.1% | Tier 4 | $12 million |
| Carbidopa / levodopa | 100% | Tier 2 | $121 million |
| Carbinoxamine maleate | 16.9% | Tier 2 | $945 thousand |
| Carbzah (carbinoxamine maleate) | 0.4% | Tier 1 | no 2024 match |
| Cardamyst (etripamil) | 0.3% | Tier 5 | no 2024 match |
| Cardizem (diltiazem hydrochloride) | under 0.1% | Tier 1 | $826 thousand |
| Cardura (doxazosin) | 0.5% | Tier 4 | $1 million |
| Carglumic acid | 99% | Tier 5 | $574 thousand |
| Carisoprodol | 12.5% | Tier 1 | $4 million |
| Carnitor (levocarnitine) | under 0.1% | Tier 1 | $272 thousand |
| Carteolol hydrochloride | 97.5% | Tier 2 | $454 thousand |
| Cartia (diltiazem hydrochloride) | 99.7% | Tier 2 | $7 million |
| Carvedilol | 100% | Tier 1 | $135 million |
| Carvedilol phosphate | 21.8% | Tier 4 | $32 million |
| Casodex (bicalutamide) | under 0.1% | Tier 1 | $237 thousand |
| Caspofungin acetate | 78% | Tier 4 | $1 million |
Show the other 137 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Cayston (aztreonam) | 100% | Tier 5 | $34 million |
| Cefaclor | 99.8% | Tier 2 | $567 thousand |
| Cefadroxil | 100% | Tier 2 | $7 million |
| Cefazolin | 100% | Tier 4 | $4 million |
| Cefdinir | 100% | Tier 2 | $35 million |
| Cefepime | 100% | Tier 4 | $20 million |
| Cefixime | 100% | Tier 4 | $2 million |
| Cefotetan | 69% | Tier 4 | no 2024 match |
| Cefoxitin | 100% | Tier 4 | $391 thousand |
| Cefpodoxime | 100% | Tier 4 | $26 million |
| Cefprozil | 96.2% | Tier 2 | $711 thousand |
| Ceftaroline fosamil | 88.8% | Tier 5 | no 2024 match |
| Ceftazidime | 100% | Tier 4 | $2 million |
| Ceftriaxone | 100% | Tier 4 | $23 million |
| Cefuroxime | 100% | Tier 2 | $17 million |
| Celebrex (celecoxib) | under 0.1% | Tier 1 | $14 million |
| Celecoxib | 100% | Tier 2 | $165 million |
| Celexa (citalopram) | under 0.1% | Tier 1 | $3 million |
| Cellcept (mycophenolate mofetil) | 2.1% | Tier 5 | $4 million |
| Celontin (methsuximide) | 3.2% | Tier 4 | $249 thousand |
| Cephalexin | 100% | Tier 1 | $58 million |
| Cequa (cyclosporine) | 2.9% | Tier 4 | $77 million |
| Cerdelga (eliglustat) | 35.8% | Tier 5 | $42 million |
| Cetirizine hydrochloride | 83.5% | Tier 2 | $214 thousand |
| Cevimeline hydrochloride | 48.8% | Tier 4 | $19 million |
| Chantix (varenicline) | 0.1% | Tier 4 | $10 thousand |
| Chemet (succimer) | 69.1% | Tier 5 | $92 thousand |
| Chlordiazepoxide hydrochloride | 26.7% | Tier 1 | $1 million |
| Chlordiazepoxide hydrochloride / clidinium bromide | 4.8% | Tier 4 | $6 million |
| Chlorhexidine gluconate | 100% | Tier 1 | $14 million |
| Chloroquine phosphate | 100% | Tier 2 | $400 thousand |
| Chlorpromazine hydrochloride | 100% | Tier 4 | $53 million |
| Chlorthalidone | 100% | Tier 2 | $48 million |
| Chlorzoxazone | 36% | Tier 2 | $15 million |
| Cholbam (cholic acid) | 21.3% | Tier 5 | $6 million |
| Cholestyramine resin | 99.9% | Tier 2 | no 2024 match |
| Cibinqo (abrocitinib) | 4.8% | Tier 5 | $17 million |
| Ciclopirox | 99.9% | Tier 2 | $40 million |
| Cilastatin / imipenem | 100% | Tier 4 | $4 million |
| Cilostazol | 100% | Tier 2 | $17 million |
| Ciloxan (ciprofloxacin) | 29.5% | Tier 3 | $2 million |
| Cimduo (lamivudine / tenofovir disoproxil fumarate) | 100% | Tier 5 | $264 thousand |
| Cimetidine | 67.6% | Tier 2 | $6 million |
| Cimzia (certolizumab pegol) | 6.5% | Tier 5 | $284 million |
| Cinacalcet | 100% | Tier 4 | $85 million |
| Cinryze (C1 esterase inhibitor, human) | 11.4% | Tier 5 | $33 million |
| Cipro (ciprofloxacin) | 5.2% | Tier 4 | $421 thousand |
| Cipro HC (ciprofloxacin / hydrocortisone) | 30.2% | Tier 4 | $4 million |
| Ciprofloxacin | 100% | Tier 1 | $33 million |
| Ciprofloxacin / dexamethasone | 79.3% | Tier 4 | $35 million |
| Ciprofloxacin / hydrocortisone | 31.6% | Tier 4 | no 2024 match |
| Citalopram | 100% | Tier 1 | $49 million |
| Cladribine | 1.2% | Tier 5 | $23 thousand |
| Claravis (isotretinoin) | 96.3% | Tier 4 | $593 thousand |
| Clarinex-D (desloratadine / pseudoephedrine sulfate) | 1.1% | Tier 3 | no 2024 match |
| Clarithromycin | 100% | Tier 2 | $5 million |
| Clemastine fumarate | 17.4% | Tier 2 | $20 million |
| Clemsza (clemastine fumarate) | 0.4% | Tier 1 | no 2024 match |
| Clenpiq (citric acid / magnesium oxide / picosulfate sodium) | 39.8% | Tier 3 | $26 million |
| Cleocin (clindamycin) | 3.6% | Tier 4 | $120 thousand |
| Cleocin-T (clindamycin) | under 0.1% | Tier 1 | no 2024 match |
| Climara (estradiol) | 2.6% | Tier 4 | $3 million |
| Climara Pro (estradiol / levonorgestrel) | 20.7% | Tier 4 | $4 million |
| Clindacin (clindamycin) | 42.9% | Tier 4 | $24 thousand |
| Clindamycin | 100% | Tier 2 | $43 million |
| Clindamycin phosphate / tretinoin | 0.4% | Tier 2 | no 2024 match |
| Clindesse (clindamycin) | 0.2% | Tier 4 | $56 thousand |
| Clinimix (alanine and 15 more ingredients) | 63.3% | Tier 4 | $31 thousand |
| Clinimix E (alanine and 20 more ingredients) | 26.6% | Tier 4 | $77 thousand |
| Clinisol 15 (alanine and 16 more ingredients) | 58.5% | Tier 4 | no 2024 match |
| Clinolipid (olive oil / soybean oil) | 65% | Tier 4 | $7 million |
| Clobazam | 100% | Tier 4 | $22 million |
| Clobetasol propionate | 97.8% | Tier 2 | $127 million |
| Clocortolone | 3.4% | Tier 4 | $190 thousand |
| Clodan (clobetasol propionate) | 58.7% | Tier 4 | $2 thousand |
| Clomipramine hydrochloride | 100% | Tier 4 | $14 million |
| Clonazepam | 100% | Tier 2 | $71 million |
| Clonidine | 100% | Tier 4 | $61 million |
| Clonidine hydrochloride | 100% | Tier 1 | $24 million |
| Clopidogrel | 100% | Tier 1 | $154 million |
| Clorazepate dipotassium | 100% | Tier 4 | $11 million |
| Clotrimazole | 100% | Tier 2 | $22 million |
| Clozapine | 100% | Tier 3 | $95 million |
| Clozaril (clozapine) | under 0.1% | Tier 1 | $12 million |
| Coartem (artemether / lumefantrine) | 100% | Tier 4 | $83 thousand |
| Cobenfy (trospium chloride / xanomeline) | 100% | Tier 5 | $3 million |
| Codeine sulfate | 23.8% | Tier 4 | $975 thousand |
| Colchicine | 100% | Tier 2 | $76 million |
| Colchicine / probenecid | 100% | Tier 2 | $2 million |
| Colesevelam hydrochloride | 73.9% | Tier 4 | $48 million |
| Colestid (colestipol hydrochloride) | under 0.1% | Tier 1 | $41 thousand |
| Colestipol hydrochloride | 100% | Tier 3 | $45 million |
| Colistin | 100% | Tier 4 | $4 million |
| Combigan (brimonidine tartrate / timolol) | 67.5% | Tier 3 | $162 million |
| Combipatch (estradiol / norethindrone acetate) | 22.2% | Tier 4 | $5 million |
| Combivent (albuterol / ipratropium bromide) | 100% | Tier 4 | $388 million |
| Cometriq (cabozantinib) | 100% | Tier 5 | $3 million |
| Complera (emtricitabine / rilpivirine / tenofovir disoproxil fumarate) | 23.2% | Tier 5 | $23 million |
| Compro (prochlorperazine) | 81.5% | Tier 4 | $1 million |
| Conexxence (denosumab-bnht) | 10.1% | Tier 3 | no 2024 match |
| Constulose (lactulose) | 97.4% | Tier 2 | $5 million |
| Copaxone (glatiramer acetate) | 16.2% | Tier 5 | $257 million |
| Copiktra (duvelisib) | 100% | Tier 5 | $31 million |
| Cordran (flurandrenolide) | 2.3% | Tier 4 | $3 million |
| Cortef (hydrocortisone) | under 0.1% | Tier 1 | $612 thousand |
| Cortrophin (corticotropin) | 6.9% | Tier 5 | $130 million |
| Cosentyx (secukinumab) | 74.3% | Tier 5 | $1.6 billion |
| Cosopt (dorzolamide / timolol) | under 0.1% | Tier 1 | $634 thousand |
| Cotellic (cobimetinib) | 100% | Tier 5 | $8 million |
| Cozaar (losartan potassium) | under 0.1% | Tier 1 | $4 million |
| Crenessity (crinecerfont) | 3.5% | Tier 5 | no 2024 match |
| Creon (amylase / lipase / protease) | 97.6% | Tier 3 | $1.5 billion |
| Cresemba (isavuconazonium sulfate) | 100% | Tier 5 | $123 million |
| Crestor (rosuvastatin calcium) | under 0.1% | Tier 1 | $32 million |
| Crexont (carbidopa / levodopa) | 0.1% | Tier 4 | $2 million |
| Crinone (progesterone) | 16.8% | Tier 4 | $55 thousand |
| Cromolyn sodium | 100% | Tier 2 | $8 million |
| Crotamiton | 0.7% | Tier 1 | no 2024 match |
| Crotan (crotamiton) | 0.7% | Tier 1 | $4 million |
| Cryselle 28 (ethinyl estradiol / norgestrel) | 96.2% | Tier 2 | no 2024 match |
| Ctexli (chenodeoxycholate) | 18% | Tier 5 | no 2024 match |
| Cuvrior (trientine tetrahydrochloride) | 5.4% | Tier 5 | $2 million |
| Cyclobenzaprine hydrochloride | 99.6% | Tier 1 | $64 million |
| Cyclophosphamide | 100% | Tier 3 | $2 million |
| Cycloserine | 53.7% | Tier 5 | no 2024 match |
| Cycloset (bromocriptine) | 13.2% | Tier 4 | $2 million |
| Cyclosporine | 100% | Tier 4 | $305 million |
| Cyclosporine, modified | 100% | Tier 4 | $7 million |
| Cyltezo (adalimumab-adbm) | 9.4% | Tier 5 | $58 million |
| Cyproheptadine hydrochloride | 57.3% | Tier 4 | $5 million |
| Cyred (desogestrel / ethinyl estradiol) | 93.8% | Tier 2 | no 2024 match |
| Cystadane (betaine) | 4.5% | Tier 5 | $1 million |
| Cystadrops (cysteamine) | 15.9% | Tier 5 | $3 million |
| Cystagon (cysteamine) | 96.2% | Tier 4 | $58 thousand |
| Cystaran (cysteamine) | 93.9% | Tier 5 | $2 million |
| Cytomel (liothyronine sodium) | 1.9% | Tier 4 | $414 thousand |
| Cytotec (misoprostol) | 0.2% | Tier 1 | $27 thousand |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans